Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent GVHD After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer

NCT00975975 is registered in ClinicalTrials.gov with Indiana University as lead sponsor.

NCT NCT00975975
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00975975 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent GVHD After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer
Lead sponsor
Indiana University
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2009
Completion date
November 30, 2013
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphocytic leukemia, acute myelogenous leukemia, anemia, aplastic, chronic lymphocytic leukemia, chronic myelogenous leukemia, hemoglobinuria, paroxysmal, hodgkin's disease, multiple myeloma, myelodysplasia, myelofibrosis, non-hodgkin's lymphoma